NASDAQ:VVUS - VIVUS Stock Price, Forecast & News

VIVUS trades on the NASDAQ under the ticker symbol "VVUS."

Shares of VIVUS reverse split on Tuesday, September 11th 2018. The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 10th 2018. An investor that had 100 shares of VIVUS stock prior to the reverse split would have 10 shares after the split.

VIVUS, Inc. (NASDAQ:VVUS) posted its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.30. The biopharmaceutical company earned $17.97 million during the quarter, compared to the consensus estimate of $19.13 million. View VIVUS's Earnings History.

VIVUS is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for VIVUS.

VIVUS will be holding an earnings conference call on Tuesday, March 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

News stories about VVUS stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. VIVUS earned a news impact score of 1.1 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the immediate future. View News Stories for VIVUS.

VIVUS saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 749,400 shares, an increase of 12.6% from the January 30th total of 665,300 shares. Based on an average daily volume of 609,600 shares, the days-to-cover ratio is presently 1.2 days. Currently, 8.0% of the company's stock are short sold. View VIVUS's Current Options Chain.

Some companies that are related to VIVUS include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other VIVUS investors own include Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Novavax (NVAX), Inovio Pharmaceuticals (INO), Melinta Therapeutics (MLNT), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD), Arena Pharmaceuticals (ARNA), BioCryst Pharmaceuticals (BCRX) and Geron (GERN).

Shares of VVUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VVUS stock can currently be purchased for approximately $2.09.

VIVUS has a market capitalization of $22.24 million and generates $65.06 million in revenue each year. The biopharmaceutical company earns $-36,950,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. VIVUS employs 57 workers across the globe.View Additional Information About VIVUS.

The official website for VIVUS is http://www.vivus.com/.

VIVUS's mailing address is 900 E. HAMILTON AVENUE SUITE 550, CAMPBELL CA, 95008. The biopharmaceutical company can be reached via phone at 650-934-5200 or via email at [email protected]